AIMS/HYPOTHESIS: Obesity increases the risk of developing type 2 diabetes mellitus, characterised by impaired insulin-mediated glucose uptake in peripheral tissues. Liver X receptor (LXR) is a positive regulator of adipocyte glucose transport in murine models and a possible target for diabetes treatment. However, the levels of LXRα are increased in obese adipose tissue in humans. We aimed to investigate the transcriptome of LXR and the role of LXR in the regulation of glucose uptake in primary human adipocytes. METHODS: The insulin responsiveness of human adipocytes differentiated in vitro was characterised, adipocytes were treated with the LXR agonist GW3965 and global transcriptome profiling was determined by microarray, followed by quantitative RT-PCR (qRT-PCR), western blot and ELISA. Basal and insulin-stimulated glucose uptake was measured and the effect on plasma membrane translocation of glucose transporter 4 (GLUT4) was assayed. RESULTS: LXR activation resulted in transcriptional suppression of several insulin signalling genes, such as AKT2, SORBS1 and CAV1, but caused only minor changes (<15%) in microRNA expression. Activation of LXR impaired the plasma membrane translocation of GLUT4, but not the expression of its gene, SLC2A4. LXR activation also diminished insulin-stimulated glucose transport and lipogenesis in adipocytes obtained from overweight individuals. Furthermore, AKT2 expression was reduced in obese adipose tissue, and AKT2 and SORBS1 expression was inversely correlated with BMI and HOMA index. CONCLUSIONS/ INTERPRETATION: In contrast to murine models, LXR downregulates insulin-stimulated glucose uptake in human adipocytes from overweight individuals. This could be due to suppression of Akt2, c-Cbl-associated protein and caveolin-1. These findings challenge the idea of LXR as a drug target in the treatment of diabetes.
AIMS/HYPOTHESIS: Obesity increases the risk of developing type 2 diabetes mellitus, characterised by impaired insulin-mediated glucose uptake in peripheral tissues. Liver X receptor (LXR) is a positive regulator of adipocyte glucose transport in murine models and a possible target for diabetes treatment. However, the levels of LXRα are increased in obese adipose tissue in humans. We aimed to investigate the transcriptome of LXR and the role of LXR in the regulation of glucose uptake in primary human adipocytes. METHODS: The insulin responsiveness of human adipocytes differentiated in vitro was characterised, adipocytes were treated with the LXR agonist GW3965 and global transcriptome profiling was determined by microarray, followed by quantitative RT-PCR (qRT-PCR), western blot and ELISA. Basal and insulin-stimulated glucose uptake was measured and the effect on plasma membrane translocation of glucose transporter 4 (GLUT4) was assayed. RESULTS:LXR activation resulted in transcriptional suppression of several insulin signalling genes, such as AKT2, SORBS1 and CAV1, but caused only minor changes (<15%) in microRNA expression. Activation of LXR impaired the plasma membrane translocation of GLUT4, but not the expression of its gene, SLC2A4. LXR activation also diminished insulin-stimulated glucose transport and lipogenesis in adipocytes obtained from overweight individuals. Furthermore, AKT2 expression was reduced in obese adipose tissue, and AKT2 and SORBS1 expression was inversely correlated with BMI and HOMA index. CONCLUSIONS/ INTERPRETATION: In contrast to murine models, LXR downregulates insulin-stimulated glucose uptake in human adipocytes from overweight individuals. This could be due to suppression of Akt2, c-Cbl-associated protein and caveolin-1. These findings challenge the idea of LXR as a drug target in the treatment of diabetes.
Authors: Karianne Solaas; Vanessa Legry; Kjetil Retterstol; Paul R Berg; Kirsten B Holven; Jean Ferrières; Philippe Amouyel; Sigbjorn Lien; Javier Romeo; Jara Valtueña; Kurt Widhalm; Jonatan R Ruiz; Jean Dallongeville; Serena Tonstad; Helge Rootwelt; Bente Halvorsen; Marit S Nenseter; Kare I Birkeland; Per M Thorsby; Aline Meirhaeghe; Hilde I Nebb Journal: BMC Med Genet Date: 2010-10-12 Impact factor: 2.103
Authors: C A Kim; Marc Delépine; Emilie Boutet; Haquima El Mourabit; Soazig Le Lay; Muriel Meier; Mona Nemani; Etienne Bridel; Claudia C Leite; Debora R Bertola; Robert K Semple; Stephen O'Rahilly; Isabelle Dugail; Jacqueline Capeau; Mark Lathrop; Jocelyne Magré Journal: J Clin Endocrinol Metab Date: 2008-01-22 Impact factor: 5.958
Authors: Atsushi Miura; Mini P Sajan; Mary L Standaert; Gautam Bandyopadhyay; Dawn M Franklin; Renee Lea-Currie; Robert V Farese Journal: Biochemistry Date: 2003-12-09 Impact factor: 3.162
Authors: Beth A Griesel; Juston Weems; Robert A Russell; E Dale Abel; Kenneth Humphries; Ann Louise Olson Journal: Diabetes Date: 2010-01-26 Impact factor: 9.461
Authors: Annie M L Pettersson; Juan R Acosta; Christel Björk; Johan Krätzel; Britta Stenson; Lennart Blomqvist; Nathalie Viguerie; Dominique Langin; Peter Arner; Jurga Laurencikiene Journal: Diabetologia Date: 2015-06-27 Impact factor: 10.122
Authors: Sara Palacios-Ortega; Maider Varela-Guruceaga; Fermín Ignacio Milagro; José Alfredo Martínez; Carlos de Miguel Journal: PLoS One Date: 2014-04-21 Impact factor: 3.240